In late 2008 Tengion direction faces a challenging dilemma. In light of the financial disasters, the firm needs to manage cash burn by prioritizing its R&D efforts. CEO Nichtberger needs to advocate to the board which of two promising new medical treatments to keep developing while placing the other on hold.
In comparing both alternatives, a host of factors need to be contemplated - these range from assessing the regulatory challenges, making challenges, promotion challenges (in particular pricing), and partnering challenges. Each of the treatments would target an unique patient population, that differ in size and makeup. Tengion must also contemplate how quickly it might expect to bring each of the two treatments to market. The decision could have important long-term consequences for the greatest survival of the business and success.
Tengion Bringing Regenerative Medicine to Life case study solution
PUBLICATION DATE: October 30, 2009 PRODUCT #: 510031-PDF-ENG
This is just an excerpt. This case is about SALES & MARKETING
Related Case Solutions & Analyses:
Ivey School of Business: The Doctoral Tracking Database
Baleno: Expanding Retail Operations in China
The Pharmaceutical Industry
Blue Mountain Resorts Ltd.: The Night Skiing Decision
Newmont Mining Corp. and a Mercury Spill in Peru (A)
Primacy: Global Design from India
Bain Capital & Dollarama
The Financial Cockpit: Three Levers And One Flight Plan
Droga5: Launching Jay-Z’s Decoded
Chocolates El Rey, Spanish Version
